stoxline Quote Chart Rank Option Currency Glossary
AIM ImmunoTech Inc. (AIM)
0.4201  -0.005 (-1.18%)    06-18 10:06
Open: 0.4267
High: 0.4267
Volume: 38,504
Pre. Close: 0.4251
Low: 0.42
Market Cap: 24(M)
Technical analysis
2024-06-18 9:46:54 AM
Short term     
Mid term     
Targets 6-month :  0.54 1-year :  0.64
Resists First :  0.46 Second :  0.54
Pivot price 0.39
Supports First :  0.37 Second :  0.31
MAs MA(5) :  0.41 MA(20) :  0.39
MA(100) :  0.41 MA(250) :  0.48
MACD MACD :  0 Signal :  -0.1
%K %D K(14,3) :  75.8 D(3) :  71.6
RSI RSI(14): 52.9
52-week High :  0.75 Low :  0.31
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ AIM ] has closed below upper band by 30.6%. Bollinger Bands are 16.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.45 - 0.45 0.45 - 0.45
Low: 0.4 - 0.4 0.4 - 0.4
Close: 0.42 - 0.43 0.43 - 0.43
Company Description

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's products include Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, prostate and pancreatic cancer, myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat genital warts, a sexually transmitted disease. It has agreements with UMN Pharma Inc.; Japanese National Institute of Infectious Diseases; Shionogi & Co., Ltd.; Polysciences Inc.; and University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.

Headline News

Mon, 17 Jun 2024
Reviewing AIM ImmunoTech (NYSE:AIM) & Genocea Biosciences (NASDAQ:GNCAQ) - Defense World

Mon, 10 Jun 2024
AIM ImmunoTech to Participate in the Virtual Investor Pitch Conference - GlobeNewswire

Mon, 03 Jun 2024
AIM ImmunoTech to Participate in the Virtual Investor Lunch Break Series - GlobeNewswire

Fri, 31 May 2024
AIM ImmunoTech Announces Pricing of $2.0 Million Registered Direct Offering - GlobeNewswire

Mon, 06 May 2024
AIM ImmunoTech Completes cGMP Manufacturing of Clinical Vials of Ampligen® - Yahoo Finance

Tue, 30 Apr 2024
AIM ImmunoTech reports progress in pancreatic cancer drug trial - Clinical Trials Arena

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 0 (M)
Shares Float 49 (M)
Held by Insiders 4.467e+007 (%)
Held by Institutions 8.5 (%)
Shares Short 446 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -2.312e+007
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -17 %
Return on Assets (ttm) 732.6 %
Return on Equity (ttm) -39.6 %
Qtrly Rev. Growth 193000 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth -0.5 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -18 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio -0.1
Price to Book value 0
Price to Sales 0
Price to Cash Flow -0.03
Stock Dividends
Dividend 0
Forward Dividend 439660
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android